Imagion Biosystems Ltd

Imagion Biosystems pioneering medical imaging with 'printer and ink' business model

Imagion Biosystems (ASX:IBX) president and CEO Bob Proulx tells Proactive Investors that the company is commercialising a new form of medical imaging that it developed for the early, non-invasive detection of cancer that uses biosafe nano-particles.

Proulx explains the medical case as well as the business case behind the technology, saying "in the medical imaging space today there's no consumable that goes with it... with our technology, because it includes both the measuring instrument and an injectable component, there's the classic printer-ink business model. We think that will be attractive for our commercial partner because now you'll be able to not only sell and install and service the instrument, but you'll also have the consumable that goes with each of the new tests that we bring to market."

Quick facts: Imagion Biosystems Ltd

Price: $0.05

Market: ASX
Market Cap: $14.57 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imagion Biosystems Ltd named herein, including the promotion by the Company of Imagion Biosystems Ltd in any Content on the Site, the Company...



Imagion Biosystems receives FDA confirmation that breast cancer technology...

Imagion Biosystems (ASX:IBX) executive chairman Bob Proulx updates Proactive Investors on the company receiving US Food and Drug Administration (FDA) confirmation that its breast cancer detection technology is a breakthrough device. This approval expedites the development process for...

4 weeks, 1 day ago

2 min read